Neurocrine Biosciences Inc (NBIX) Actualités

Neurocrine Biosciences to Participate at Investor Conferences in December

Neurocrine Biosciences to Participate at Investor Conferences in December PR Newswire SAN DIEGO, Nov. 26, 2024...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and...

Neurocrine Biosciences to Participate at Investor Conferences in November

Neurocrine Biosciences to Participate at Investor Conferences in November PR Newswire SAN DIEGO, Nov. 5, 2024...

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With...

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR...

Form 8-K - Current report

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results PR...

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea...